Argo Biopharma Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
200
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Argo Biopharma General Information
Description
Developer of a clinical-stage biotechnology platform designed to advance RNAi therapeutics for a wide range of diseases, including cardiovascular, viral, metabolic, and rare conditions. The company offers a robust and diverse pipeline of RNAi drug candidates, enabling healthcare providers to address complex medical needs and improve treatment outcomes for patients worldwide.
Contact Information
Website
www.argobiopharma.comCorporate Office
- 4th Floor, Zhongtong Building
- Number 581 Shenkuo Road, Pudong New Area
- Shanghai, 200000
- China
Corporate Office
- 4th Floor, Zhongtong Building
- Number 581 Shenkuo Road, Pudong New Area
- Shanghai, 200000
- China
Argo Biopharma Timeline
Argo Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 26-Nov-2024 | Completed | Clinical Trials - Phase 2 | |||
| 5. Secondary Transaction - Private | 22-Sep-2023 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 15-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 22-Mar-2022 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 01-Nov-2021 | $5M | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | 27-Apr-2021 | $5M | $5M | Completed | Pre-Clinical Trials |
Argo Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Argo Biopharma Patents
Argo Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233323-A1 | Compositions and methods for inhibiting expression of apolipoprotein c3 (apoc3) | Pending | 07-May-2025 | ||
| WO-2026219328-A1 | Compositions and methods for inhibiting expression of angiopoietin-like 4 (angptl4) | Pending | 18-Apr-2025 | ||
| WO-2026184659-A1 | Methods for treating hepatitis b virus (hbv) infection | Pending | 05-Mar-2025 | ||
| WO-2026175408-A1 | Method of reducing agt expression for treating cardiovascular disease | Pending | 24-Feb-2025 | ||
| WO-2026153459-A1 | Compositions and methods for inhibiting expression of complement component 3 (c3) | Pending | 17-Jan-2025 |
Argo Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Argo Biopharma Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Healthib Capital | PE/Buyout | Minority |
Argo Biopharma FAQs
-
When was Argo Biopharma founded?
Argo Biopharma was founded in 2021.
-
Where is Argo Biopharma headquartered?
Argo Biopharma is headquartered in Shanghai, China.
-
What is the size of Argo Biopharma?
Argo Biopharma has 200 total employees.
-
What industry is Argo Biopharma in?
Argo Biopharma’s primary industry is Drug Discovery.
-
Is Argo Biopharma a private or public company?
Argo Biopharma is a Private company.
-
What is Argo Biopharma’s current revenue?
The current revenue for Argo Biopharma is .
-
How much funding has Argo Biopharma raised over time?
Argo Biopharma has raised $68.1M.
-
Who are Argo Biopharma’s investors?
Healthib Capital has invested in Argo Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
